• EdU Imaging Kits (488) for CRC Proliferation

  2026-08-12

  Use EdU Imaging Kits (488) to connect colorectal cancer pathway perturbations with direct S-phase DNA synthesis measurements in microscopy or flow cytometry workflows. This guide translates circEIF2S2 research into practical assay design, controls, optimization steps, and troubleshooting without confusing DNA synthesis with total cell growth.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Bench Guide

  2026-08-11

  This scenario-based guide explains how Cy3 Goat Anti-Human IgG (H+L) Antibody, SKU K1208, can strengthen human IgG detection alongside viability, proliferation, and cytotoxicity workflows. It covers spectral compatibility, controls, storage, optimization, interpretation, and practical vendor-selection criteria.

• Mitomycin C: Mechanism and Cancer Research Guide

  2026-08-11

  Mitomycin C is an antitumor antibiotic that forms covalent DNA adducts and inhibits DNA replication. Its documented activity includes TRAIL sensitization in p53-deficient colon cancer models, making it useful for apoptosis signaling research and cancer biology workflows.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-08-10

  Breen and colleagues developed a drug-sensitized Saccharomyces cerevisiae platform that detects TOR/mTOR inhibitors at substantially lower concentrations than a wild-type yeast assay. The study validates the system with Torin1, omipalisib, AZD8055, and aminophylline, while showing no evidence of TOR inhibition for several tested compounds, including nebivolol.

• Lopinavir: From HIV Potency to MERS Assays

  2026-08-09

  Lopinavir and ABT-378 offer a useful model for connecting molecular HIV protease inhibition with cell-based antiviral screening. This article explains how to interpret potency, resistance, serum effects, and the MERS-CoV repurposing evidence without overstating cross-pathogen conclusions.

• DNase I (RNase-free) for Clean RNA Workflows

  2026-08-08

  Build cleaner RNA extraction, RT-PCR, and in vitro transcription workflows with targeted DNA digestion and RNase-conscious handling. The same enzyme also supports carefully titrated chromatin and RNA:DNA hybrid studies, provided metal-ion chemistry and downstream cleanup are controlled.

• Epmedin C Targets DON Immunotoxicity in Chicken Macrophages

  2026-08-07

  The reference study connects low-dose deoxynivalenol exposure with caspase-1/IL-1β activation, elevated reactive oxygen species, and impaired immune function in chickens. By combining network pharmacology, molecular docking, macrophage assays, coculture experiments, and chick validation, it identifies epmedin C as a candidate intervention for DON-associated immunotoxicity.

• BRCA2 Controls PARP1 Retention and RAD51 Filament Stability

  2026-08-07

  This study elucidates how BRCA2 directly prevents PARP inhibitor-mediated retention of PARP1 at DNA repair sites, thus safeguarding RAD51 filament stability during homologous recombination. The findings clarify the molecular basis for the sensitivity of BRCA2-deficient tumors to PARP inhibitors, with important implications for the design and interpretation of homologous recombination deficient cancer treatment studies.

• Nonselective β-Blockers Impair Hematopoietic Regeneration Po

  2026-08-06

  This study reveals that nonselective β-adrenergic receptor antagonists, such as carvedilol, disrupt hematopoietic regeneration following hematopoietic cell transplantation (HCT) in mice and humans. The findings highlight the crucial role of β2- and β3-adrenergic signaling in bone marrow recovery and inform the experimental design of studies involving β-blockers in hematologic and regenerative contexts.

• Structural Basis of Nipah Virus Polymerase: Insights for Ant

  2026-08-06

  This study delivers the first high-resolution structures of the Nipah virus L-P polymerase complex, illuminating how the viral replication machinery operates at the molecular level. These findings provide essential structural data to inform the rational design of targeted antiviral agents against Nipah and related paramyxoviruses.

• DNase I (RNase-free): Molecular Precision in RNA Vaccine Res

  2026-08-05

  Explore how DNase I (RNase-free) empowers next-generation RNA vaccine workflows and advanced molecular biology. This deep-dive unpacks mechanistic detail, practical protocols, and unique assay optimizations for DNA removal in RNA extraction—providing a scientific edge distinct from prior content.

• SGI-1027: Precision Epigenetic Modulation and Assay Optimiza

  2026-08-05

  Unlock the full potential of SGI-1027 as a DNA methyltransferase inhibitor in advanced epigenetics research. This article provides a deep-dive into assay optimization, unique mechanistic insights, and practical protocol parameters for cancer epigenetics workflows.

• IEM 1460: AMPA Receptor Blocker for Precision Neuroprotectio

  2026-08-04

  IEM 1460, a selective AMPA receptor blocker from APExBIO, empowers researchers to dissect excitotoxicity and synaptic modulation with high specificity. This guide translates recent breakthroughs and best practices into actionable workflows for neuroprotection assays and troubleshooting.

• Selective Human ClpP Activation Induces Cell Cycle Arrest in

  2026-08-04

  The referenced study introduces ZK53 as a structurally novel, highly selective activator of human mitochondrial ClpP, demonstrating its capacity to disrupt oxidative phosphorylation and induce cell cycle arrest in lung squamous cell carcinoma (LUSC) models. These findings provide mechanistic insights with direct implications for mitochondrial-targeted cancer research.

• Anlotinib Hydrochloride: Translating Angiogenesis Inhibition

  2026-08-03

  This thought-leadership article explores the mechanistic and strategic value of Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor for translational researchers. Integrating molecular insights, rigorous experimental validation, and workflow guidance, it delivers actionable recommendations for leveraging Anlotinib in advanced cancer research, with direct links to evidence and protocol parameters.

8407 records 3/561 page Previous Next 12345 下5页 Last page